DRKS00033360尚未招募不适用
Investigating the role of the glucagon-like peptide 1 system on foodcue-induced brain activation – a non-interventional longitudinalfunctional magnetic resonance imaging study - SONIC
Zentralinstitut für Seelische Gesundheit, Klinik für Abhängiges Verhalten und Suchtmedizin, repräsentiert durch0 个研究点目标入组 60 人开始时间: 2024年1月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •Men and women between the ages of 18 and 60 who are receiving treatment with Wegovy® or Ozempic® (active ingredient: semaglutide) due to obesity/overweight
- •- Sufficient ability to communicate with the investigators and to answer questions in oral and written form
- •- Ability to give consent after receiving and understanding all the research-related information (Fully Informed Consent)
排除标准
- •- Persons suffering from a mental illness (exceptions: Anxiety disorders, mild to moderate depression, nicotine consumption, alcohol use disorder)
- •- Contraindications for functional magnetic resonance imaging (e.g. metal implants and/or pacemakers that are not suitable for MRI)
- •- Use of psychotropics, painkillers containing opiates or drugs within the last ten days
- •- Withdrawal symptoms at the time of the examination (CIWA score > 3)
- •- Breath alcohol concentration > 0.0 per mille at the time of the examination
- •- Positive drug screening (amphetamines/ecstasy, opiates, cocaine, barbiturates, cannabis, benzodiazepines)
- •- Women who are pregnant or breastfeeding
- •- Current severe somatic comorbidities:
- •Liver cirrhosis or severely impaired renal function, severe heart failure,
- •pre-existing epilepsy
- •- Acute suicidal tendencies or acute danger to self or others
研究者
相似试验
已完成
不适用
Effect of glucagon-like-peptide-1 (GLP-1) on left ventricular function during percutaneous coronary intervention (PCI)ISRCTN77442023Papworth Hospital NHS Foundation Trust (UK)40
招募中
4 期
The role of glucagon-like peptide-1 (GLP-1) in glycaemic, triglyceride and energy expenditure responses to fat in type 2 diabetes.ACTRN12614001117606Dr Tanya Little20
进行中（未招募）
1 期
iraglutide to Short Bowel Syndrome, a cross-over studyShort bowel syndrome (SBS) is a clinical situation with reduced absorptive mucosal surface due to extensive surgical resection. SBS leads to increased intestinal losses of fluids and electrolytesrestricted oral/enteral nutrition to reduce intestinal lossesdisease-related hypophagialack of adaptive hyperphagiaaccelerated gastrointestinal transit timeMedDRA version: 19.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2015-000825-35-DKRigshospitalet Blegdamsvej16
已完成
1 期
The effect of the glucagon-like peptide-1 analogue, exenatide, on duodenal motility and flow events, and small intestinal transit in healthy humans and type 2 diabetes mellitus.ACTRN12608000428369Royal Adelaide Hospital24
已完成
2 期
Effects of Glucagon-Like Peptide-1 (GLP-1) administration on gastric emptying during periods of hyperglycaemia in healthy volunteers.Glycaemic control and gastric emptyingMetabolic and Endocrine - Other metabolic disordersACTRN12613001384741Dr Mark Plummer15